About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
exaly
›
Institutions
›
Duke University
›
Institute of Statistics and Decision Sciences
›
Top Articles
Institute of Statistics and Decision Sciences
Duke University
537
Articles
31.6K
Citations
2.8
avg. Impact Factor
89
h-index
Most Cited Articles of Institute of Statistics and Decision Sciences in 2017
Title
Journal
Year
Citations
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
New England Journal of Medicine
2017
1.1K
Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial
JAMA - Journal of the American Medical Association
2017
636
Survival and Neurodevelopmental Outcomes among Periviable Infants
New England Journal of Medicine
2017
254
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Lancet Haematology,the
2017
93
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)
Journal of Clinical Oncology
2017
77
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials
Lancet Haematology,the
2017
66
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
Clinical Cancer Research
2017
50
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance)
Annals of Surgery
2017
43
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with -mutated acute myeloid leukemia: CALGB 11001
Blood Advances
2017
42
Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
Breast Cancer Research and Treatment
2017
41
Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601
European Journal of Cancer Care
2017
30
Dynamically Timed Stimulation of Corticolimbic Circuitry Activates a Stress-Compensatory Pathway
Biological Psychiatry
2017
16
Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503)
Breast Cancer Research and Treatment
2017
11
The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
PLoS ONE
2017
10
The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines
JAMA Cardiology
2017
10
A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803
Oncologist
2017
10
Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Oncologist
2017
7
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
AAPS Journal
2017
6
Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
Annals of Oncology
2017
3
HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL
Hematological Oncology
2017
1
BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE)
Hematological Oncology
2017
Schools/Departments
The list of schools/departments is not comprehensive since it is common to drop the department in the affiliation.
site/software ©
exaly
; All materials licenced under
CC by-SA
.